FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134963806> ?p ?o ?g. }

• W3134963806 endingPage "1193" @default.
• W3134963806 startingPage "1182" @default.
• W3134963806 abstract "Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin–kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing. The purpose of this study was to conduct a patient-level pooled analysis from 3 phase 3 studies of inclisiran. Participants with heterozygous familial hypercholesterolemia (ORION-9 [Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)]), atherosclerotic cardiovascular disease (ASCVD) (ORION-10 [Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol]), or ASCVD and ASCVD risk equivalents (ORION-11 [Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol]) taking maximally tolerated statin therapy, with or without other LDL-C–lowering agents, were randomly assigned in a 1:1 ratio to receive either inclisiran or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter for 540 days. The coprimary endpoints were the placebo-corrected percentage change in LDL-C level from baseline to day 510 and the time-adjusted percentage change in LDL-C level from baseline after day 90 to day 540. Levels of other atherogenic lipoproteins and treatment-emergent adverse events were also assessed. A total of 3,660 participants (n = 482, n = 1,561, and n = 1,617 from ORION-9, -10, and -11, respectively) underwent randomization. The placebo-corrected change in LDL-C with inclisiran at day 510 was −50.7% (95% confidence interval: −52.9% to −48.4%; p < 0.0001). The corresponding time-adjusted change in LDL-C was −50.5% (95% confidence interval: −52.1% to −48.9%; p < 0.0001). Safety was similar in both groups. Treatment-emergent adverse events at the injection site were more frequent with inclisiran than placebo (5.0% vs. 0.7%), but were predominantly mild, and none were severe or persistent. Liver and kidney function tests, creatine kinase values, and platelet counts did not differ between groups. These pooled safety and efficacy data show that inclisiran, given twice yearly in addition to maximally tolerated statin therapy with or without other LDL-C lowering agents, is an effective, safe, and well-tolerated treatment to lower LDL-C in adults with heterozygous familial hypercholesterolemia, ASCVD, or ASCVD risk equivalents." @default.
• W3134963806 created "2021-03-15" @default.
• W3134963806 creator A5006206326 @default.
• W3134963806 creator A5026884252 @default.
• W3134963806 creator A5028480812 @default.
• W3134963806 creator A5040044369 @default.
• W3134963806 creator A5044425699 @default.
• W3134963806 creator A5062745101 @default.
• W3134963806 creator A5065063579 @default.
• W3134963806 creator A5075454148 @default.
• W3134963806 creator A5075595313 @default.
• W3134963806 creator A5077253460 @default.
• W3134963806 creator A5077848934 @default.
• W3134963806 creator A5080414941 @default.
• W3134963806 creator A5080753934 @default.
• W3134963806 creator A5082625254 @default.
• W3134963806 date "2021-03-01" @default.
• W3134963806 modified "2023-10-17" @default.
• W3134963806 title "Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis" @default.
• W3134963806 cites W1971293448 @default.
• W3134963806 cites W2149264664 @default.
• W3134963806 cites W2160347316 @default.
• W3134963806 cites W2164089346 @default.
• W3134963806 cites W2180653297 @default.
• W3134963806 cites W2496801530 @default.
• W3134963806 cites W2527622017 @default.
• W3134963806 cites W2570432860 @default.
• W3134963806 cites W2596179513 @default.
• W3134963806 cites W2609543937 @default.
• W3134963806 cites W2769252393 @default.
• W3134963806 cites W2780610639 @default.
• W3134963806 cites W2805474259 @default.
• W3134963806 cites W2897257410 @default.
• W3134963806 cites W2899997727 @default.
• W3134963806 cites W2905226841 @default.
• W3134963806 cites W2950258410 @default.
• W3134963806 cites W2980876689 @default.
• W3134963806 cites W3011005820 @default.
• W3134963806 cites W3012265841 @default.
• W3134963806 cites W3129818723 @default.
• W3134963806 cites W3183857127 @default.
• W3134963806 doi "https://doi.org/10.1016/j.jacc.2020.12.058" @default.
• W3134963806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33663735" @default.
• W3134963806 hasPublicationYear "2021" @default.
• W3134963806 type Work @default.
• W3134963806 sameAs 3134963806 @default.
• W3134963806 citedByCount "92" @default.
• W3134963806 countsByYear W31349638062021 @default.
• W3134963806 countsByYear W31349638062022 @default.
• W3134963806 countsByYear W31349638062023 @default.
• W3134963806 crossrefType "journal-article" @default.
• W3134963806 hasAuthorship W3134963806A5006206326 @default.
• W3134963806 hasAuthorship W3134963806A5026884252 @default.
• W3134963806 hasAuthorship W3134963806A5028480812 @default.
• W3134963806 hasAuthorship W3134963806A5040044369 @default.
• W3134963806 hasAuthorship W3134963806A5044425699 @default.
• W3134963806 hasAuthorship W3134963806A5062745101 @default.
• W3134963806 hasAuthorship W3134963806A5065063579 @default.
• W3134963806 hasAuthorship W3134963806A5075454148 @default.
• W3134963806 hasAuthorship W3134963806A5075595313 @default.
• W3134963806 hasAuthorship W3134963806A5077253460 @default.
• W3134963806 hasAuthorship W3134963806A5077848934 @default.
• W3134963806 hasAuthorship W3134963806A5080414941 @default.
• W3134963806 hasAuthorship W3134963806A5080753934 @default.
• W3134963806 hasAuthorship W3134963806A5082625254 @default.
• W3134963806 hasBestOaLocation W31349638061 @default.
• W3134963806 hasConcept C126322002 @default.
• W3134963806 hasConcept C164705383 @default.
• W3134963806 hasConcept C2778163477 @default.
• W3134963806 hasConcept C2779120738 @default.
• W3134963806 hasConcept C2779134260 @default.
• W3134963806 hasConcept C2909478654 @default.
• W3134963806 hasConcept C3017906399 @default.
• W3134963806 hasConcept C71924100 @default.
• W3134963806 hasConcept C95190672 @default.
• W3134963806 hasConceptScore W3134963806C126322002 @default.
• W3134963806 hasConceptScore W3134963806C164705383 @default.
• W3134963806 hasConceptScore W3134963806C2778163477 @default.
• W3134963806 hasConceptScore W3134963806C2779120738 @default.
• W3134963806 hasConceptScore W3134963806C2779134260 @default.
• W3134963806 hasConceptScore W3134963806C2909478654 @default.
• W3134963806 hasConceptScore W3134963806C3017906399 @default.
• W3134963806 hasConceptScore W3134963806C71924100 @default.
• W3134963806 hasConceptScore W3134963806C95190672 @default.
• W3134963806 hasFunder F4320307778 @default.
• W3134963806 hasIssue "9" @default.
• W3134963806 hasLocation W31349638061 @default.
• W3134963806 hasOpenAccess W3134963806 @default.
• W3134963806 hasPrimaryLocation W31349638061 @default.
• W3134963806 hasRelatedWork W2596275816 @default.
• W3134963806 hasRelatedWork W2894591464 @default.
• W3134963806 hasRelatedWork W2945169015 @default.
• W3134963806 hasRelatedWork W2949823575 @default.
• W3134963806 hasRelatedWork W2965833795 @default.
• W3134963806 hasRelatedWork W3090329158 @default.
• W3134963806 hasRelatedWork W3196213296 @default.
• W3134963806 hasRelatedWork W4285297618 @default.
• W3134963806 hasRelatedWork W4293256751 @default.

• next